Lv51
1366 积分 2020-08-09 加入
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
8小时前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5天前
已完结
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
6天前
已完结
Targeted Therapies in Non–Small Cell Lung Cancer
6天前
已完结
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
6天前
已完结
The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications
9天前
已完结
The next generation of antibody–drug conjugates
14天前
已完结
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
19天前
已完结
Discovery of a Novel Tripeptide Linker that Broadens the Therapeutic Window of Auristatin-Based Antibody–Drug Conjugates by Reducing Bone Marrow Toxicity
19天前
已完结
皖公网安备34019202002308
